Ology Bioservices Wins Two Department of Defense Awards Totaling More Than $135 Million ALACHUA, Fla.--(BUSINESS WIRE)--Ology Bioservices, Inc., a biologics contract development and manufacturing organization (CDMO), announced today that the Department of Defense (DOD), through its Platforms for Rapid Integrated Solutions for Medical Countermeasures (PRISM) office, has awarded the company with two [...]
Ology Bioservices Appoints Vaccines and Biologics Manufacturing Industry Veteran, Brandon Brega, as Chief Operating Officer ALACHUA, Fla.--(BUSINESS WIRE)--Ology Bioservices, Inc., a biologics contract development and manufacturing organization (CDMO), announced today the appointment of vaccines and biologics manufacturing industry expert, Brandon Brega, to the position of Chief Operating Officer, effective immediately. In this [...]
Ology Bioservices to Present at the 30thAnnual Piper Jaffray Healthcare Conference ALACHUA, Fla., November 20, 2018 - - Ology Bioservices, Inc., a biologics contract development and manufacturing organization (CDMO), announced today that management will present at the 30thAnnual Piper Jaffray Healthcare conference, to be held at the Lotte New York Palace hotel, [...]
Ology Bioservices Strengthens Management Team with Addition of Timothy Cooke, Ph.D. as Senior Vice President of Commercial Business ALACHUA, Fla.--(BUSINESS WIRE)--Ology Bioservices, Inc., a biologics contract development and manufacturing organization (CDMO), announced today that industry veteran Timothy Cooke, Ph.D., has joined the Company as Senior Vice President of Commercial Business. “Tim brings [...]
Ology Bioservices Wins $8.4 Million Defense Department Award to Produce Anti-Ebola Medical Countermeasure ALACHUA, Fla.--(BUSINESS WIRE)--Ology Bioservices, Inc., a biologics contract development and manufacturing organization (CDMO), announced today that it was awarded an Other Transaction Agreement (OTA) to support the Joint Project Manager Medical Countermeasure Systems (JPM-MCS), a component of the Joint [...]
Barrett PN, Terpening SJ, Snow D, Cobb RR, Kistner O. Vero cell technology for rapid development of inactivated whole virus vaccines for emerging viral diseases. Expert Review of Vaccines. 2017;16(9):883-894. Read More >
Ni Y, Springer MJ, Guo J, et al. Development of a synthetic Vi polysaccharide vaccine for typhoid fever. Vaccine. 2017;35:7121–7126. Read Here >
Li M, Lee D, Obi CR, Freeberg JK, Farr-Jones S, Tomic MT. An ambient temperature-stable anti toxin of nine co-formulated antibodies for botulism caused by serotypes A, B and E. PLoSONE 2018.13(5):e0197011. Read Here >
Ball JP, Springer MJ, Ni Y, Finger-Baker I, Martinez J, Hahn J, et al. Intranasal delivery of a bivalent norovirus vaccine formulated in an in situ gelling dry powder. PLoSONE. 2017;12(5):e0177310 Read Here >
Malone RW, Homan J, Callahan MV, Glasspool-Malone J, Damodaran L, Schneider ADB, et al. Zika virus: medical countermeasure development challenges. 2016 PLoS Negl Trop Dis. 10(3): e0004530. Read Here >
COVID-19 Letter